Xeris Biopharma Holdings Inc (STU:2B30)
€ 3.302 0.14 (4.43%) Market Cap: 490.65 Mil Enterprise Value: 684.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Q3 2024 Xeris Biopharma Holdings Inc Earnings Call Transcript

Nov 08, 2024 / 01:30PM GMT
Release Date Price: €3.17 (+3.80%)
Operator

Hello and welcome to the Xeris BioPharma third quarter, 2024 financial results conference call. My name is Harry and I'll be your operator today. All lines are currently in listen-only mode and there'll be an opportunity for Q&A after management's prepared remarks. If you would like to enter the queue for questions, please dial star word by one on your telephone keypad.

I would now like to hand the conference over to Allison Way, Senior Vice President of Investor Relations and Corporate Communications. Thank you. Please go ahead.

Allison Wey
Xeris Biopharma Holdings Inc - Senior Vice President Investor Relations & Corporate Communications

Thank you, Gary and Good morning. We appreciate you joining our third quarter results call today. I'm joined by John Shannon, our CEO and Steve Piper, our CFO this morning we issued a press release with our detailed results which can be found on our website. After our prepared remarks. We will open the line for questions before we begin. I would like to remind you that this call will contain forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot